GT200600439A - Derivados de propilamina sustituida y metodos para su utilización - Google Patents

Derivados de propilamina sustituida y metodos para su utilización

Info

Publication number
GT200600439A
GT200600439A GT200600439A GT200600439A GT200600439A GT 200600439 A GT200600439 A GT 200600439A GT 200600439 A GT200600439 A GT 200600439A GT 200600439 A GT200600439 A GT 200600439A GT 200600439 A GT200600439 A GT 200600439A
Authority
GT
Guatemala
Prior art keywords
disorders
derivatives
methods
fibromialgia
distributed
Prior art date
Application number
GT200600439A
Other languages
English (en)
Inventor
Casey Cameron Mccomas
Puwen Zhang
Eugene Anthony Terefenko
An Thien Vu
Stephen Todd Cohn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600439A publication Critical patent/GT200600439A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE PROPILAMINA SUSTITUIDA DE FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, A LAS COMPOSICIONES QUE CONTIENEN DICHOS DERIVADOS Y MÉTODOS DE USO PARA LA PREVENCIÓN Y TRATAMIENTO DE CONDICIONES QUE MEJORAN CON LA RECAPTACIÓN DE MONOAMINA INCLUSO, ENTRE OTROS, LOS SÍNTOMAS VASOMOTORES (SVM), DISFUNICIÓN SEXUAL, TRASTORNOS GASTROINTESTINALES Y GENITOURINARIOS, SÍNDROMES DE FATIGA CRÓNICA, SÍNDROME DE FIBROMIALGIA, TRASTORNOS DEL SISTEMA NERVIOSO Y SUS COMBINACIONES ESPECIALMENTE AQUELLAS CONDICIONES SELECCIONADAS DEL GRUPO FORMADO POR UN TRASTORNO DEPRESIVO MAYOR, SÍNTOMA VASOMOTORES, INCONTINENCIA POR ESTRÉS E INCONTINENCIA URINARIA URGENTE, FIBROMIALGIA, DOLOR, NEUROPATÍA DIABÉTICA Y SUS COMBINACIONES.
GT200600439A 2005-09-29 2006-09-27 Derivados de propilamina sustituida y metodos para su utilización GT200600439A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72205205P 2005-09-29 2005-09-29

Publications (1)

Publication Number Publication Date
GT200600439A true GT200600439A (es) 2007-09-19

Family

ID=37808290

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600439A GT200600439A (es) 2005-09-29 2006-09-27 Derivados de propilamina sustituida y metodos para su utilización

Country Status (12)

Country Link
US (1) US7687529B2 (es)
EP (1) EP1934178A2 (es)
JP (1) JP2009510094A (es)
CN (1) CN101277933A (es)
AR (1) AR056097A1 (es)
AU (1) AU2006297207A1 (es)
BR (1) BRPI0616458A2 (es)
CA (1) CA2623423A1 (es)
GT (1) GT200600439A (es)
PE (1) PE20070584A1 (es)
TW (1) TW200800888A (es)
WO (1) WO2007041257A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103108873A (zh) * 2010-07-16 2013-05-15 皮拉马尔企业有限公司 作为激酶抑制剂的取代的咪唑并喹啉衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3306399A (en) 1998-03-02 1999-09-20 Eli Lilly And Company Fluoxetine hydrochloride for decreasing hot flashes
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
EP1322622B1 (en) * 2000-09-19 2012-10-31 Sprout Pharmaceuticals, Inc. New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
AU2005250116B2 (en) 2004-06-01 2011-01-20 F. Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor

Also Published As

Publication number Publication date
CN101277933A (zh) 2008-10-01
WO2007041257A3 (en) 2007-06-28
WO2007041257A2 (en) 2007-04-12
US20070072928A1 (en) 2007-03-29
EP1934178A2 (en) 2008-06-25
TW200800888A (en) 2008-01-01
CA2623423A1 (en) 2007-04-12
PE20070584A1 (es) 2007-07-09
AU2006297207A1 (en) 2007-04-12
US7687529B2 (en) 2010-03-30
BRPI0616458A2 (pt) 2011-06-21
JP2009510094A (ja) 2009-03-12
AR056097A1 (es) 2007-09-19

Similar Documents

Publication Publication Date Title
ECSP066899A (es) Derivados fenilaminopropanol y métodos de uso
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
CL2007002356A1 (es) Sistema de liberacion farmaceutica que comprende flibanserina y por lo menos un excipiente farmaceuticamentre aceptable; y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, del sueno y sexuales, entre otros.
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
CL2008000212A1 (es) Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre
CL2011002849A1 (es) Composicion anti-inflamatoria que comprende microorganismos sometidos a tratamiento a por lo menos 71,5 grados celsius durante por lo menos 1 segundo; uso de una composicion para tratar o prevenir padecimientos inflamatorios; metodos para proporcionar los microorganismos.
CR9517A (es) Metodo y aparato de caneria enrrollable bajo tierra y parcialmente sumergida
PA8663501A1 (es) Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
EA200970471A1 (ru) Микроорганизмы или их фракции, обеспечивающие активацию клеточного иммунитета против углеводов
DK1830881T3 (da) Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
AR058983A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
AR048912A1 (es) Inmunoglobulinas anti-nogo
CL2008002744A1 (es) Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2.
ECSP099490A (es) Métodos de fabricación y uso de compuestos y composiciones
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
SV2009002851A (es) Inhibidores de la pde y combinaciones de los mismos para el tratamiento de trastornos urologicos
PA8628101A1 (es) Derivados fenilaminopropanol y metodos de uso
UY39188A (es) Imidazopiridazinas como moduladores de il-17
CR10866A (es) Derivados de aril sulfamida y metodos para su uso
EA200801120A1 (ru) Нафтильные производные в качестве ингибиторов агрегирования бета-амилоида
UY28925A1 (es) Nuevos derivados de aminopiridina y su uso como fármacos
PA8615001A1 (es) Derivados n-heterociclo sustituidos y metodos de uso de los mismos
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.